Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications. (30th April 2014)

• Record Type: Journal Article
• Authors: Tomaschitz, Andreas; Piecha, Grzegorz; Ritz, Eberhard; Meinitzer, Andreas; Haas, Josef; Pieske, Burkert; Wiecek, Andrzej; Rus-Machan, Jutta; Toplak, Hermann; März, Winfried; Verheyen, Nicolas; Gaksch, Martin; Amrein, Karin; Kraigher-Krainer, Elisabeth; Fahrleitner-Pammer, Astrid; Pilz, Stefan
• Is Part Of: Clinical and experimental hypertension. Volume 37:Number 2(2015)
• Page Start: 108
• Page End: 115
• Publication Date: 2014-04-30
• Subjects: Aldosterone -- cardiovascular -- hypertension -- marinobufagenin -- primary aldosteronism; Hypertension -- Chemotherapy -- Periodicals; Hypotensive agents -- Periodicals; 616.132
• DOI: 10.3109/10641963.2014.913604
• Languages: English
• ISSNs: 1064-1963

Abstract

Abstract: Background : The cardiotonic steroid marinobufagenin (MBG) is increasingly suggested to be responsible for some of the cardiovascular injury that has been previously attributed to aldosterone. We examined the clinical correlates of circulating MBG concentrations in hypertensive patients and tested the hypothesis that MBG serves as a reliable diagnostic tool for detecting primary aldosteronism (PA). Methods : Plasma MBG concentrations (mean: 0.51 ± 0.25 nmol/l) were measured in the morning fasting samples in 20 patients with PA and 20 essential hypertensive (EH) controls matched for age, sex, body mass index, renal function, urinary sodium and intake of antihypertensive medication (mean age: 51.6 years; 52.2% women). Results : Overall, plasma MBG was directly correlated with plasma aldosterone, aldosterone to active renin ratio (AARR), diastolic blood pressure, mean carotid intima-media thickness, serum sodium, urinary protein to creatinine ratio and inversely with serum potassium levels. Plasma MBG levels were significantly higher in patients with PA compared to EH (mean: 0.68 ± 0.12 versus 0.35 ± 0.24 nmol/l; p < 0.001). ROC analysis yielded a greater AUC for plasma MBG compared to the AARR, PAC and serum potassium levels for detecting PA. Youden's Index analyses yielded the optimal plasma MBG cut-off score for diagnosing PA at > 0.49 nmol/l with specificity and sensitivity values of 0.85 and 0.95, respectively, which were higher than those at the optimum AARR cut-off at > 3.32 ng/dl/µU/ml. Conclusions : In a well-characterized cohort, values of plasma MBG were significantly related to clinical correlates of cardiovascular and renal disease. Plasma MBG emerged as a valuable alternative to the AARR for screening of PA.